Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genome sequencing project to benefit future treatment development
“This information will help scientists understand how influenza viruses evolve and spread,” commented NIH director Dr Elias Zerhouni, “and it will aid in the development of new flu
“This information will help scientists understand how influenza viruses evolve and spread,” commented NIH director Dr Elias Zerhouni, “and it will aid in the development of new flu
In laboratory studies, the researchers isolated a protein, caveolin-1, showing that in breast cancer cells this protein can enhance cell death in response to the use of Taxol,
The Entelos Cardiovascular PhysioLab platform was originally built in collaboration with Pfizer. “The pharmaceutical and medical communities recognize the importance of treating complex conditions much earlier in the
The company is developing Xcytrin as an anti-cancer agent for the treatment of non-small cell lung cancer patients with brain metastases. The FDA stated that the company’s application
According to Access, each of Somanta’s drug candidates acts by a unique mechanism of action, and has the potential to target a wide range of different cancer types.
The plant employs 2,500 people of whom 1,800 are in supply and manufacturing positions. The cuts will be made over the next three years. Despite the losses, the
Bicillin L-A (penicillin G benzathine injectable suspension) is the first product available from this facility. Bicillin L-A, administered via deep intramuscular injection, has been used effectively for more
Genentech stated that, if necessary, it would appeal the decision to reject the patent through all appropriate means of review within the Patent Office and the courts. The
A study involving mice showed that a hormone called prolactin triggers production of myelin, a fatty substance that protects nerve cells in the brain and spinal cord. In
The termination agreement stipulates that Dyax will receive all the assets of the joint venture, including a 100% ownership of DX-88 worldwide, as well as a $17 million